Literature DB >> 9310487

Conjugation of blocked ricin to an anti-CD19 monoclonal antibody increases antibody-induced cell calcium mobilization and CD19 internalization.

A C Goulet1, V S Goldmacher, J M Lambert, C Baron, D C Roy, E Kouassi.   

Abstract

CD19 (B4) is a signal transduction molecule restricted to the B-cell lineage and the target of the immunotoxin anti-B4-blocked ricin (anti-B4-bR), which is composed of the monoclonal antibody (MoAb) anti-B4 and the modified plant toxin blocked ricin. To explore the influence of conjugation of blocked ricin to anti-B4 on functional activation of CD19, we investigated the effects of anti-B4-bR, and that of unconjugated anti-B4, on intracellular calcium mobilization and ligand/receptor internalization. The data showed that anti-B4-bR was more potent than anti-B4 in triggering cell calcium mobilization. Two other immunotoxins that bind to the B-cell surface, anti-CD20-bR and anti-CD38-bR, were devoid of the calcium increasing effect of anti-B4-bR. Furthermore, anti-B4 conjugated to ricin A-chain was also without effect in Namalwa cells, indicating that the ricin B-chain component was required for anti-B4-bR effect. Anti-B4-bR-induced calcium mobilization was inhibited in the presence of lactose, yet the calcium response induced by cross-linking anti-B4-bR with a second step antibody was not affected. The extent of CD19 modulation induced by anti-B4-bR was higher than that induced by anti-B4, and lactose dampened the effect of the immunotoxin down to that of the MoAb. Moreover, the number of internalized immunotoxin molecules was higher than that of unconjugated MoAb. Although a mechanism involving dimerization of the immunotoxin cannot be excluded, our findings suggest that the residual binding activity of the blocked ricin B-chain to cell surface molecules plays an important role in the greater calcium fluxes and greater internalization rate of anti-B4-bR, and is of functional significance in the mechanism of intoxication of cells by the immunotoxin.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9310487

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  In vitro evaluation of 213Bi-rituximab versus external gamma irradiation for the treatment of B-CLL patients: relative biological efficacy with respect to apoptosis induction and chromosomal damage.

Authors:  Katia Vandenbulcke; Filip De Vos; Fritz Offner; Jan Philippé; Christos Apostolidis; Roger Molinet; Tuomo K Nikula; Klaus Bacher; Virginie de Gelder; Anne Vral; Christophe Lahorte; Hubert Thierens; Rudi A Dierckx; Guido Slegers
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-07-03       Impact factor: 9.236

2.  Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab.

Authors:  Rhona Stein; Zhengxing Qu; Susan Chen; David Solis; Hans J Hansen; David M Goldenberg
Journal:  Blood       Date:  2006-06-15       Impact factor: 22.113

3.  Preclinical studies of targeted therapies for CD20-positive B lymphoid malignancies by Ofatumumab conjugated with auristatin.

Authors:  Zhao Hui Li; Qian Zhang; Hai Bin Wang; Ya Nan Zhang; Ding Ding; Li Qiang Pan; David Miao; Shi Xu; Chen Zhang; Pei Hua Luo; Hua Naranmandura; Shu Qing Chen
Journal:  Invest New Drugs       Date:  2013-08-01       Impact factor: 3.850

4.  Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy.

Authors:  Daniel A Vallera; Hua Chen; Andrew R Sicheneder; Angela Panoskaltsis-Mortari; Elizabeth P Taras
Journal:  Leuk Res       Date:  2009-03-26       Impact factor: 3.156

5.  Bioengineering a unique deimmunized bispecific targeted toxin that simultaneously recognizes human CD22 and CD19 receptors in a mouse model of B-cell metastases.

Authors:  Daniel A Vallera; Seunguk Oh; Hua Chen; Yanqun Shu; Arthur E Frankel
Journal:  Mol Cancer Ther       Date:  2010-06-08       Impact factor: 6.009

6.  Activating Autophagy Enhanced the Antitumor Effect of Antibody Drug Conjugates Rituximab-Monomethyl Auristatin E.

Authors:  Yichen Wang; Xuyao Zhang; Jiajun Fan; Wei Chen; Jingyun Luan; Yanyang Nan; Shaofei Wang; Qicheng Chen; Yujie Zhang; Youling Wu; Dianwen Ju
Journal:  Front Immunol       Date:  2018-08-03       Impact factor: 7.561

7.  High CD21 expression inhibits internalization of anti-CD19 antibodies and cytotoxicity of an anti-CD19-drug conjugate.

Authors:  Gladys S Ingle; Pamela Chan; J Michael Elliott; Wesley S Chang; Hartmut Koeppen; Jean-Philippe Stephan; Suzie J Scales
Journal:  Br J Haematol       Date:  2007-11-07       Impact factor: 6.998

Review 8.  Global Plant Stress Signaling: Reactive Oxygen Species at the Cross-Road.

Authors:  Nasser Sewelam; Kemal Kazan; Peer M Schenk
Journal:  Front Plant Sci       Date:  2016-02-23       Impact factor: 5.753

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.